Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

Heart failure (HF) is a progressive condition with periods of apparent stability and repeated worsening HF events. Over time, unless optimization of HF treatment, worsening HF events become more frequent and patients enter into a cycle of recurrent events with high morbidity and mortality. In patien...

Descripción completa

Detalles Bibliográficos
Autores: González Juanatey, José Ramón, Comín Colet, Josep, Pascual Figal, Domingo, Bayés Genís, Antoni, Cepeda, Jose Maria, García Pinilla, José Manuel, García Quintana, Antonio, Manzano, Luis, Zamorano, Jose Luis
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/197710
Acceso en línea:https://hdl.handle.net/2445/197710
Access Level:acceso abierto
Palabra clave:Insuficiència cardíaca
Comorbiditat
Heart failure
Comorbidity
id ES_91a6a3ce6d737232d4fa3bbc8b40ae15
oai_identifier_str oai:recercat.cat:2445/197710
network_acronym_str ES
network_name_str España
repository_id_str
spelling Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of VericiguatGonzález Juanatey, José RamónComín Colet, JosepPascual Figal, DomingoBayés Genís, AntoniCepeda, Jose MariaGarcía Pinilla, José ManuelGarcía Quintana, AntonioManzano, LuisZamorano, Jose LuisInsuficiència cardíacaComorbiditatHeart failureComorbidityHeart failure (HF) is a progressive condition with periods of apparent stability and repeated worsening HF events. Over time, unless optimization of HF treatment, worsening HF events become more frequent and patients enter into a cycle of recurrent events with high morbidity and mortality. In patients with HF there is an activation of deleterious neurohormonal pathways, such as the renin angiotensin aldosterone system and the sympathetic system, and an inhibition of protective pathways, including natriuretic peptides and guanylate cyclase. Therefore, HF burden can be reduced only through a holistic approach that targets all neurohormonal systems. In this context, vericiguat may play a key role, as it is the only HF drug that activates the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate system. On the other hand, it has been described relevant disparities in the management of HF population. Consequently, it is necessary to homogenize the management of these patients, through an integrated patient-care pathway that should be adapted at the local level. In this context, the development of new technologies (ie, video call, specific platforms, remote control devices, etc.) may be very helpful. In this manuscript, a multidisciplinary group of experts analyzed the current evidence and shared their own experience to provide some recommendations about the therapeutic optimization of patients with recent worsening HF, with a particular focus on vericiguat, and also about how the integrated patient-care pathway should be performed.Informa UK Limited2023202320232023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion11 p.application/pdfapplication/pdfhttps://hdl.handle.net/2445/197710Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.2147/PPA.S400403Patient Preference and Adherence, 2023, vol. 17, p. 839-849https://doi.org/10.2147/PPA.S400403cc by-nc (c) González Juanatey, José Ramón et al, 2023http://creativecommons.org/licenses/by-nc/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1977102026-05-29T05:05:01Z
dc.title.none.fl_str_mv Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
title Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
spellingShingle Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
González Juanatey, José Ramón
Insuficiència cardíaca
Comorbiditat
Heart failure
Comorbidity
title_short Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
title_full Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
title_fullStr Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
title_full_unstemmed Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
title_sort Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
dc.creator.none.fl_str_mv González Juanatey, José Ramón
Comín Colet, Josep
Pascual Figal, Domingo
Bayés Genís, Antoni
Cepeda, Jose Maria
García Pinilla, José Manuel
García Quintana, Antonio
Manzano, Luis
Zamorano, Jose Luis
author González Juanatey, José Ramón
author_facet González Juanatey, José Ramón
Comín Colet, Josep
Pascual Figal, Domingo
Bayés Genís, Antoni
Cepeda, Jose Maria
García Pinilla, José Manuel
García Quintana, Antonio
Manzano, Luis
Zamorano, Jose Luis
author_role author
author2 Comín Colet, Josep
Pascual Figal, Domingo
Bayés Genís, Antoni
Cepeda, Jose Maria
García Pinilla, José Manuel
García Quintana, Antonio
Manzano, Luis
Zamorano, Jose Luis
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Insuficiència cardíaca
Comorbiditat
Heart failure
Comorbidity
topic Insuficiència cardíaca
Comorbiditat
Heart failure
Comorbidity
description Heart failure (HF) is a progressive condition with periods of apparent stability and repeated worsening HF events. Over time, unless optimization of HF treatment, worsening HF events become more frequent and patients enter into a cycle of recurrent events with high morbidity and mortality. In patients with HF there is an activation of deleterious neurohormonal pathways, such as the renin angiotensin aldosterone system and the sympathetic system, and an inhibition of protective pathways, including natriuretic peptides and guanylate cyclase. Therefore, HF burden can be reduced only through a holistic approach that targets all neurohormonal systems. In this context, vericiguat may play a key role, as it is the only HF drug that activates the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate system. On the other hand, it has been described relevant disparities in the management of HF population. Consequently, it is necessary to homogenize the management of these patients, through an integrated patient-care pathway that should be adapted at the local level. In this context, the development of new technologies (ie, video call, specific platforms, remote control devices, etc.) may be very helpful. In this manuscript, a multidisciplinary group of experts analyzed the current evidence and shared their own experience to provide some recommendations about the therapeutic optimization of patients with recent worsening HF, with a particular focus on vericiguat, and also about how the integrated patient-care pathway should be performed.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/197710
url https://hdl.handle.net/2445/197710
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.2147/PPA.S400403
Patient Preference and Adherence, 2023, vol. 17, p. 839-849
https://doi.org/10.2147/PPA.S400403
dc.rights.none.fl_str_mv cc by-nc (c) González Juanatey, José Ramón et al, 2023
http://creativecommons.org/licenses/by-nc/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by-nc (c) González Juanatey, José Ramón et al, 2023
http://creativecommons.org/licenses/by-nc/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 11 p.
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Informa UK Limited
publisher.none.fl_str_mv Informa UK Limited
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413407559516160
score 15,81155

Similares en LA Referencia